Neuropsychological Evaluation for Early Diagnosis of PSP

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

112 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2018-03-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuropsychological Assessment of Cognitive Decline in Patients With a Definite Parkinson's Disease

NCT01113242

Parkinson Disease Dementia

COMPLETED

The MOTIVE-PSP Initiative (Progressive Supranuclear Palsy)

NCT04691635

Progressive Supranuclear Palsy

UNKNOWN

tDCS Plus Physical Therapy for Progressive Supranuclear Palsy

NCT04237948

Progressive Supranuclear Palsy Parkinsonism Parkinsonian Disorders

COMPLETED NA

Effect of Remote Cognitive Intervention in Patients With Parkinson's Disease During the COVID-19 Pandemic

NCT05476302

Parkinson Disease COVID-19 Mild Cognitive Impairment

COMPLETED

DAT SPECT and Procedural Motor Skills in Parkinson's Disease

NCT03076307

Parkinson Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Progressive Supranuclear Palsy Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PSP patients

Patients suffering from Progressive Supranuclear Palsy (PSP)

Cognitive evaluation

Intervention Type BEHAVIORAL

An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.

PD Patients

Patients suffering from Parkinson's disease (PD)

Cognitive evaluation

Intervention Type BEHAVIORAL

An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cognitive evaluation

An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients fulfilling the criteria for idiopathic PD
* Patients fulfilling the criteria for PSP

Exclusion Criteria

* Any other neurodegenerative disorders or medical conditions different from PD / PSP

Eligible Sex

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giuseppe Frazzitta, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Parkinson's disease, Movement Disorders and Brain Injury Rehabilitation, "Moriggia-Pelascini" Hospital - Via Pelascini, 3, 22015, Gravedona ed Uniti, Como, Italy